Press Releases


Half yearly report to 31 March 2021

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, announces its unaudited interim results for the six months ended 31 March 2021. Financial highlights: · Reported revenues of £4. 9 million for the six months to 31 March 2021 (H1 2020: £4.

Read more

Phase II Alzheimer’s disease contract award worth >£1m

IXICO plc, the AI data analytics company delivering insights in neuroscience, announces that it has been awarded an expansion contract by a current biopharmaceutical client to support the company’s Phase II Alzheimer’s disease clinical trial.

Read more

Contract win for new neuroinflammatory disorder

Contract extends IXICO’s CNS franchise to include a further new disease indication IXICO plc, the AI data analytics company delivering insights in neuroscience, announces that it has been selected by a current biopharmaceutical client to provide neuroimaging services for a Phase III clinical trial.

Read more

Contract win for new stroke study

New therapeutic area, broadening IXICO’s neurological footprint IXICO plc, the AI data analytics company delivering insights in neuroscience, announces that it has executed a contract to provide neuroimaging services for a new clinical trial for acute ischemic stroke with its largest pharma client.

Read more

Collaboration with Microsoft to support business scale up with global pharma

IXICO plc, the AI data analytics company delivering insights in neuroscience, announces a collaboration with Microsoft to develop its AI data analytics platform for the global pharmaceutical industry.

Read more

IXICO chosen for new Phase II Alzheimer’s disease study

IXICO plc, the AI data analytics company delivering insights in neuroscience, announces that it has been selected by a current mid-sized biopharmaceutical client to support the company’s Phase II Alzheimer’s disease clinical trial.

Read more

IXICO selected by Cyclerion for new Alzheimer’s disease study

IXICO plc, the AI data analytics company delivering insights in neuroscience, announces that it has been selected by Cyclerion Therapeutics, Inc. , a new client, to support the company’s Phase IIa clinical trial to investigate CY6463 for treatment of individuals with Alzheimer’s disease.

Read more

IXICO attending AD/PD 2021 Conference

IXICO will be presenting at the upcoming AD/PD 2021 conference taking place virtually on 9-14 March 2021. AD/PD 2021, the 15th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, is one of the most prestigious in the year and IXICO welcomes the opportunity to present.

Read more

17-24 of 63 results